NASDAQ · Biotechnology

Aura Biosciences, Inc. (AURA) Stock

$6.51 +0.70% NASDAQ: AURA Healthcare

Valuation

MetricValue
Price$6.51
Market Cap$672.85M
P/E Ratio-3.42
P/B Ratio1.83
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$9.54
52-Week Low$4.73
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-73.18%
ROA-37.63%
ROCE-42.02%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio8.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-35.0M$-60.0M$-85.0M$-96.0M$-113.0M
Net Profit$-35.0M$-59.0M$-76.0M$-87.0M$-106.0M
EPS$-1.58$-1.96$-1.93$-1.75$-1.76
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$160.0M$224.0M$255.0M$183.0M$169.0M
Total Liabilities$8.0M$28.0M$29.0M$31.0M$33.0M
Cash$149.0M$122.0M$41.0M$32.0M$60.0M
Borrowings$1.0M$21.0M$20.0M$19.0M$17.0M

Latest News

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors GlobeNewswire · Jul 8, 2026 Aura Biosciences Completes Enrollment in Phase 3 Trial of Belzupacap Sarotalocan for Early Choroidal Melanoma MT Newswires · Jun 1, 2026 Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma GlobeNewswire · Jun 1, 2026 Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances MarketBeat · May 27, 2026 Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data MarketBeat · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$-55.0M$-64.0M$-80.0M$-85.0M
Investing Cash Flow$-4.0M$-69.0M$-115.0M$68.0M$35.0M
Financing Cash Flow$0$0$2.0M$0$0
Net Cash Flow$132.0M$-27.0M$-81.0M$-9.0M$28.0M
Free Cash Flow$-35.0M$-56.0M$-65.0M$-81.0M$-85.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.36
EV / EBITDA-4.40
FCF Yield-16.30%
Quick Ratio16.82
Interest Coverage0.00
Return 1Y2.86%
Return 3Y-37.98%
Return 5Y—

Ownership

Insiders Held1.16%
Institutions Held49.37%
Institutions Float Held49.95%
Institutional HolderSharesReport Date
Matrix Capital Management Company LP6,922,8702026-03-31
Frazier Life Sciences Management, L.P. 5,100,0002026-03-31
Adage Capital Partners GP L.L.C.4,881,1252026-03-31
Long Focus Capital Management, LLC4,619,5822026-03-31
Suvretta Capital Management, LLC4,372,8842026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AKTSAktis Oncology, Inc. $17.74 -1.44% -17.01 $947.40M 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CRBPCorbus Pharmaceuticals Holdings, Inc. $5.27 -4.01% -0.95 $97.64M 0.00%
EYPTEyePoint, Inc. $3.46 +4.22% -0.91 $290.09M 0.00%
IMNMImmunome, Inc. $19.31 +1.13% -8.23 $1.85B 0.00%

About Aura Biosciences, Inc.

Aura Biosciences, Inc. is led by CEO Elisabet de los Pinos, employs 106 people, headquartered in US, publicly traded since 2021.

Aura Biosciences, Inc. (AURA) stock trades at $6.51 with a market capitalization of $672.85M. The stock is valued at a price-to-earnings (P/E) ratio of -3.42, price-to-book of 1.83, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.73 and $9.54, and currently trades 31.8% below its 52-week high.

On profitability, Aura Biosciences, Inc. generates a return on equity (ROE) of -73.18%, return on capital employed of -42.02%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides